Mediclinic International PLC (LON:MDC) has been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is GBX 645.17 ($8.35).
Several brokerages have weighed in on MDC. Credit Suisse Group dropped their price objective on Mediclinic International from GBX 660 ($8.54) to GBX 550 ($7.12) and set a “neutral” rating for the company in a report on Thursday. Barclays dropped their price objective on Mediclinic International from GBX 751 ($9.72) to GBX 700 ($9.06) and set an “overweight” rating for the company in a report on Tuesday, August 7th.
LON:MDC traded up GBX 4.60 ($0.06) during mid-day trading on Tuesday, hitting GBX 489.50 ($6.34). 1,794,100 shares of the stock were exchanged, compared to its average volume of 1,610,000. Mediclinic International has a fifty-two week low of GBX 495.40 ($6.41) and a fifty-two week high of GBX 890.18 ($11.52).
About Mediclinic International
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 49 acute care private hospitals and 2 day clinics in South Africa, and 3 hospitals in Namibia with approximately 8,095 beds; 16 acute care private hospitals with 1,677 beds, as well as 4 clinics in Switzerland; and 6 acute care private hospitals and 31 clinics with 714 beds in the United Arab Emirates.
Recommended Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.